Almirall S.A. | Balance Sheet

Fiscal year is January-December. All values EUR Millions.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
89
754
868
467
280
86
Total Accounts Receivable
138
266
189
176
147
232
Inventories
98
81
87
91
84
92
Other Current Assets
10
6
3
5
4
4
Total Current Assets
335
1,107
1,147
739
515
414
Net Property, Plant & Equipment
161
132
128
132
128
115
Total Investments and Advances
23
179
179
15
18
142
Long-Term Note Receivable
-
-
-
-
168
-
Intangible Assets
931
783
760
1,426
1,072
1,437
Other Assets
-
-
1
180
7
-
Total Assets
1,773
2,540
2,532
2,819
2,176
2,390
ST Debt & Current Portion LT Debt
27
-
-
-
-
Accounts Payable
198
218
225
237
141
Income Tax Payable
7
6
2
6
3
Other Current Liabilities
165
137
74
129
205
Total Current Liabilities
398
361
302
372
348
Long-Term Debt
254
316
316
317
250
Provision for Risks & Charges
67
93
82
90
122
Deferred Taxes
187
212
191
94
129
Other Liabilities
17
288
227
272
170
Total Liabilities
871
1,185
1,053
1,284
1,030
Common Equity (Total)
888
1,340
1,463
1,520
1,134
Total Shareholders' Equity
888
1,340
1,463
1,520
1,134
Total Equity
888
1,340
1,463
1,520
1,134
Liabilities & Shareholders' Equity
1,773
2,540
2,532
2,819
2,176
Non-Equity Reserves
13
16
17
14
13

About Almirall

View Profile
Address
Ronda General Mitre, 151
Barcelona Catalonia 08022
Spain
Employees -
Website http://www.almirall.com
Updated 07/08/2019
Almirall SA engages in the development, manufacture, storage, commercialization and sale of pharmaceutical and cosmetic products, as well as of the raw materials used in production. The company operates through the following segments: Marketing through Own Network, Marketing by Licensees, Research and Development Activity, Therapeutic Area of Dermatology in the United States, and Corporate Management and Results not assigned to Other Segments. Its products include treatments for respiratory, autoimmune, dermatological and gastrointestinal diseases.